安全网医疗环境下患者对产前游离DNA筛查的体验
研究在佛罗里达州杰克逊维尔一家联邦合格健康中心,对100名黑人和西班牙裔产科患者进行质性访谈,了解其在cfDNA作为州公共保险人群一线筛查方法推广后的体验。参与者普遍反映缺乏筛查前咨询、cfDNA健康素养有限,部分不确定是否已接受cfDNA检测,多数对cfDNA用于胎儿性别早期检测和一般胎儿健康指标感兴趣。结论认为患者体验显示知情同意和决策有限,与专业指南关于筛查前咨询的建议不一致。
要点
- 参与者描述筛查前咨询机会极少,对cfDNA或其用途的健康素养有限。
- 许多参与者不确定自己是否接受了cfDNA,尽管知晓其提供的信息。
- 多数参与者对cfDNA用于胎儿性别早期检测和作为一般胎儿健康额外指标感兴趣。
核心结论
- 患者体验显示cfDNA的知情同意和决策有限,与专业指南关于筛查前咨询的建议不一致。
- 作者认为应在安全网环境中追加投入实施cfDNA,以确保患者和提供者获得有效患者咨询和后续护理所需的支持,从而实现cfDNA的伦理实施。
研究设计与样本
- 在佛罗里达州杰克逊维尔一家联邦合格健康中心的产前或母胎医学诊所,邀请接受产前护理的黑人和西班牙裔患者参加英语或西班牙语质性访谈。
- 参与者在首次产前就诊后招募,此时通常引入cfDNA。
- 访谈转录本基于扎根理论原则进行迭代主题的质性分析。
- 共100名黑人和西班牙裔患者完成访谈(n=51非西班牙裔黑人,n=43西班牙裔,n=3西班牙裔黑人,n=3未报告/其他)。
主要发现
- 参与者描述筛查前咨询机会极少,对cfDNA或其用途的健康素养有限。
- 一些参与者认为cfDNA可对妊娠健康产生积极影响。
- 许多参与者不确定自己是否接受了cfDNA,尽管他们知晓cfDNA提供的信息。
- 多数参与者表达对cfDNA作为胎儿性别早期检测手段以及作为一般胎儿健康额外指标的兴趣。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Thirty-five states, including Florida, now cover cell-free DNA (cfDNA) screening of fetuses for all pregnant patients enrolled in state public insurance programs. We interviewed Black and Hispanic obstetric patients at a safety net clinic in Florida shortly after the state rolled out cfDNA as a first-tier screening method for publicly insured patients. METHODS: Black and Hispanic patients receiving prenatal care from a prenatal or maternal fetal medicine clinic at a federally qualified health center in Jacksonville, FL were invited to participate in a qualitative interview in English or Spanish to explore experiences and perceptions of prenatal cfDNA screening. Participants were recruited following their first prenatal visit when cfDNA is typically introduced. Interview transcripts were qualitatively analyzed for iterative themes based on principles of grounded theory. RESULTS: One hundred Black and Hispanic patients (n = 51 non-Hispanic Black, n = 43 Hispanic, n = 3 Hispanic Black, n = 3 Not Reported/Other) completed an interview. Participants described minimal opportunity for pre-screening counseling and limited health literacy about cfDNA or its uses. Some believed that cfDNA could positively impact pregnancy health. Many were unsure if they had received cfDNA even though they were aware of the information provided by it. Most participants expressed an interest in cfDNA as a means for early detection of fetal sex and as an additional indication of general fetal health. CONCLUSIONS: Patient experiences indicate limited informed consent and decision-making for cfDNA, discordant with professional guidelines on pre-screen counseling. Our findings suggest that there should be additional investment in implementing cfDNA in safety net settings to ensure that patients and providers receive the support necessary for effective patient counseling and follow-on care for the ethical implementation of cfDNA.
引用
- Riggan KA, Barwise A, Yap JQ, et al. Patient experiences with prenatal cell-free DNA screening in a safety net setting. Prenat Diagn. 2024. PMID: 38423995. doi:10.1002/pd.6541
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。